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The blood-brain barrier (BBB) plays a key role in maintaining the specialized microenvironment of the
central nervous system (CNS), and enabling communication with the systemic compartment. BBB
changes occur in several CNS pathologies. Here, we review disruptive and non-disruptive BBB changes
in systemic infections and other forms of systemic inflammation, and how these changes may affect
CNS function in health and disease. We first describe the structure and function of the BBB, and outline
the techniques used to study the BBB in vitro, and in animal and human settings. We then summarise the
evidence from a range of models linking BBB changes with systemic inflammation, and the underlying
mechanisms. The clinical relevance of these BBB changes during systemic inflammation are discussed
in the context of clinically-apparent syndromes such as sickness behaviour, delirium, and septic
encephalopathy, as well as neurological conditions such as Alzheimer’s disease and multiple sclerosis.
We review emerging evidence for two novel concepts: (1) a heightened sensitivity of the diseased, versus
healthy, BBB to systemic inflammation, and (2) the contribution of BBB changes induced by systemic
inflammation to progression of the primary disease process.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
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The effects of systemic inflammation on central nervous system
(CNS) function may be adaptive, as an appropriate response to sys-
temic upset (Hart, 1988), but deleterious effects are commonly
seen in clinical practice. Acute syndromes of CNS dysfunction are
frequently seen to accompany non-neurotropic systemic infections
such as pneumonia or urinary tract infections. In chronic condi-
tions such as multiple sclerosis or Alzheimer’s disease, systemic
inflammation can be associated with a transient or permanent
deterioration (Buljevac et al., 2002; Holmes et al., 2009).
In this review, we focus on the effects of systemic inflammation
on the blood-brain barrier (BBB), which may be desirable or dele-
terious. The foremost role of the BBB is to maintain homeostasis
for optimal brain function. BBB changes may be disruptive or
non-disruptive. Disruptive BBB changes are likely to be deleterious.
Non-disruptive changes may also be deleterious but could provide
a mechanism for communication across a morphologically intact
BBB, and without unselected compromise of the barrier functions
essential to CNS homeostasis.
2. Anatomy and function of the BBB
The anatomy of the BBB is best described at histological and
molecular levels; its function is carried out by structures at these
two levels. Histologically the BBB is a specialized multi-layered
unit composed of a thick continuous glycocalyx, non-fenestrated
endothelial cells with reduced vesicular activity and linked by tight
junctions, two basement membranes (vascular basement mem-
brane and glia limitans), and astrocytic end-feet. All elements of
this ‘neurovascular unit’ contribute to the functional BBB. At the
molecular level, there are ectoenzymes, receptors and transporters
in several of these layers which regulate or reverse traffic across
the BBB. Together, these components enable a stable CNS environ-
ment that is unique in the following ways: (1) different ionic com-
position, needed for neuronal function (2) specialized
neurotransmitter pool (3) low protein concentration, to minimize
cell proliferation (4) low exposure to systemic toxins, to minimize
neuronal damage (5) reduced traffic of inflammatory cells and
molecules, to minimize local inflammation.
3. Assessing BBB function
3.1. In vitro
A number of methods may be used to study BBB functions (He
et al., 2014). Histological techniques such as freeze-fracture andelectron microscopy permit snapshot visualisation of changes in
tight junctions and vesicles, from which changes in function can
be inferred.
Endothelial monolayers allow quantitative assessment of bar-
rier function and are a relatively simple model in which experi-
mental conditions can be easily modified (Helms et al., 2016).
Primary or immortalized human or animal brain microvascular
endothelial cells (BMECs or BMVECs) are cultured into a confluent
monolayer on permeable cell culture plate inserts (e.g. Transwell).
The solutes or cells of interest are added to the top compartment,
and the fraction that migrates through the endothelial layer into
the bottom compartment is measured. This technique allows study
of the polarity of the BBB. Measurement may employ radiolabelled
compounds or fluorescent dyes, or techniques such as enzyme-
linked immunosorbent assay (ELISA) or liquid chromatography-
mass spectrometry (LC-MS). Transendothelial electrical resistance
(TEER) across the monolayer can be measured, and reflects paracel-
lular ion flux; reduced resistance suggests opening of tight junc-
tions. The significant limitation of such models is that cells
cultured in an artificial environment will not differentiate or func-
tion appropriately, and may lack features relevant to the BBB func-
tions under investigation. Co-culture with other relevant
components such as abluminal astrocytes may improve the fidelity
of the model. Simulation of flow may also influence differentiation
of endothelial barrier characteristics (Tarbell, 2010). Endothelial
cells may be seeded onto porous hollow fibres (Stanness et al.,
1997) or microfluidic devices (Booth and Kim, 2012), to create a
three-dimensional tissue culture through which flow can be re-
created.
Isolated cerebral microvessels can be prepared from brain tis-
sue and provide a more functional model than endothelial mono-
layers, with preservation of differentiated BBB characteristics.
Importantly, transport, receptor, and metabolic systems are pre-
served, allowing detailed study of these processes (Choi and
Pardridge, 1986), as well as patch-clamp studies of membrane
ionic channels (Hoyer et al., 1991). Alternatively endothelial
plasma membrane vesicles can be isolated from microvessels, pro-
viding a useful method to compare differences between luminal
and abluminal surfaces which contribute to the polarity of the
BBB (Sánchez del Pino et al., 1992).3.2. In vivo
In vitro BBB models can never fully recapitulate the natural
microenvironment, and therefore in vivo methods are more realis-
tic. In humans, a number of techniques can be used, as summarised
Table 1
Concepts in methodology for in vivo study of BBB disruption in humans.
Concept Method Example
CNS concentration of a plasma protein not usually
synthesized within the CNS correlates with BBB
permeability
Post-mortem study of brain tissue can detect ante-mortem BBB leakage
of plasma protein
Immunohistochemistry for albumin
on brain tissue (van Vliet et al., 2007)
Paired cerebrospinal fluid (CSF) and serum analysis to estimate the ratio
of CSF to serum concentration of plasma protein
CSF/serum albumin quotient, Qalb
(Akaishi et al., 2015)
Serum concentration of a CNS protein not usually
synthesized outside the CNS correlates with BBB
permeability
Serum analysis of the CNS protein Serum S100b (Kapural et al., 2002)
Intravital injection of tracers Injection of low molecular weight paramagnetic substances before
magnetic resonance brain imaging
Dynamic contrast-enhanced
magnetic resonance imaging
(Cramer et al., 2014)
Injection of radiolabelled substances before nuclear medicine brain
imaging
Gallium injection positron emission
tomography (Iannotti et al., 1987)
Injection of radiolabelled test and BBB-impermeable reference
substances into carotid artery, or antecubital vein, and detection in
internal jugular vein
Double-indicator diffusion technique
(Knudsen, 1994)
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manipulation and observation. Experiments may employ one or
several of a wider array of tracers, injection sites, compartments
assayed, time points, detection techniques and analytical
approaches; this is illustrated in Fig. 1, grouped by steps in exper-
imental design. The combinatorial possibilities are many. For
instance, in one experiment, a radiolabelled exogenous substance
(sucrose) was delivered systemically with a single injection into
the femoral vein while arterial blood was sampled over 60 min
to follow its circulating concentration (Bickel et al., 1998), while
in another experiment the brain was perfused in situ for 30 min
with a solution of radiolabeled endogenous peptide (Nonaka
et al., 2005). At the point of sacrifice brain tissue was collected in
both experiments (i.e. the CNS compartment was assayed at one
time point) and a scintillation counter was used to quantitate
amounts of each substance. Different experimental designs call
for different analytical methods. Hence, in the first experiment
using intravenous injection, pharmacokinetic modelling was
employed to track a changing circulating concentration while in
the second experiment, the concentration of the perfusate was
known and fixed, so pharmacokinetic modelling was not required.
In experiments where the CNS compartment is assayed several
times, multiple time-point regression analysis is used (Patlak
et al., 1983; Kastin et al., 2001). The choice of analytical method
determines the index used to quantify BBB permeability, of which
there are several (Panel 6 in Fig. 1).
It is important to note that measurements of ‘permeability’ may
be inaccurate if the substance is actively transported, metabolised,
or secreted by the BBB. In addition, the experimental situation may
cause increased systemic production, or may trigger CNS produc-
tion, of an endogenous substance being used to study BBB function,
or may result in reduced systemic clearance with potential con-
founding effects.4. Disruptive and non-disruptive BBB change
Although there is a tendency to refer to the effect of systemic
inflammation on ‘BBB permeability’, this terminology can be con-
fusing, since permeability usually reflects diffusibility of sub-
stances across the BBB and traffic across the BBB is not governed
by diffusion alone. The concept of BBB permeability arose from
early studies which used solutes to measure BBB function. We
now know that BBB function is highly regulated and, while diffu-
sion is an important process, both molecules and cellular traffic
are subject to specific or regulated processes distinct from diffu-
sion. Hence we propose the terminology ‘BBB change’ whichindicates BBB responsiveness. BBB change can be disruptive or
non-disruptive, reflecting the presence or absence of physical dis-
ruption of the BBB. Disruptive BBB change is accompanied by
changes at the histological level, such as endothelial cell damage
or tight junction changes, while non-disruptive change occurs at
the molecular level. Studying the BBB using inert substances will
detect disruptive BBB change but is unlikely to detect non-
disruptive BBB change. Table 2 summarises the fundamental dif-
ferences between disruptive and non-disruptive BBB change, and
Fig. 2 illustrates their anatomical context and possible mecha-
nisms. Both disruptive and non-disruptive BBB changes may occur
in systemic inflammation, and both have important consequences.5. Disruptive BBB change in systemic inflammation
5.1. LPS models
Systemic challenge with lipopolysaccharide (LPS), an immuno-
genic component of Gram-negative bacteria, is widely used to
model systemic inflammation. A number of in vitro BMEC studies
have shown that LPS challenge results in disruptive BBB change
to ions (by TEER) (de Vries et al., 1996a) as well as solutes such
as albumin (Tunkel et al., 1991).
When administered in vivo, the effect of LPS on BBB function is
variable. In a systematic review, we analysed studies examining
disruptive BBB change after LPS challenge in vivo. Papers were
identified by searching MEDLINE and Web of Science in February
2016, as well as by collecting references from relevant articles. Var-
ious search terms were used in full and abbreviated form including
‘lipopolysaccharide’, ‘endotoxin’, ‘blood-brain barrier’, and
‘systemic inflammation’. We looked for animal studies in which a
systemically-delivered solute was assayed in the CNS after sys-
temic challenge with LPS or control. We did not include studies
examining non-disruptive BBB change involving cellular traffic.
We excluded studies if the solute could be subject to BBB transport
mechanisms, if the experiment for a particular solute was not
replicated elsewhere, if the relevant lethal dose could not be ascer-
tained for the animal model, or if the study examined solute efflux
rather than influx. In total, 22 studies were excluded, of which 68%
showed increased solute traffic after LPS challenge.
47 papers including 74 studies were eligible for analysis. Exper-
imental characteristics and results were extracted from these stud-
ies, and are available from the University of Southampton
repository at http://dx.doi.org/10.5258/SOTON/387995. 60% of
studies reported disruptive BBB change after LPS; this figure may
be subject to publication bias since papers reporting disruptive
Exogenous, e.g.
Fluorescein
Sucrose
Dextran
Endogenous, e.g.
Albumin
Immunoglobulins
  SUBSTANCE OF INTEREST1
INTRA-ARTERIAL
Single injection 
Into carotid artery
In situ brain perfusion
Brain perfused in situ
avoid substance mixing with blood
INTRAVENOUS
Single injection
Into an accessible vein 
e.g. femoral or tail vein
Infusion
Via cannula
DELIVERY OF EXOGENOUS SUBSTANCE2
Brain tissue
ISF
Implantation of microdialysis probe
CSF
Implantation of CSF cannula
Venous blood
Cannulation of cerebral vein e.g. 
sagittal sinus
Pial vessel
Exposure via cranial window
     CNS COMPARTMENT
ASSAYED     3
Single
CNS assayed for substance at a 
single time point
Multiple
Continuous assay (e.g. CSF 
cannula) in same animal, or 
different time points
     CNS DETECTION
TIME POINT   4
Dye detection
Visual inspection
Absorbance measurement
Fluorescence detection
Fluorimetry
Fluorescence imaging
Radioactive label detection
Scintillation counter
Autoradiography
Enzyme conjugate detection
Addition of chromogenic substrate
Antibody-based detection
IHC
ELISA
Heavy metal detection
EM
AAS
Mass spectrometry
   DETECTION TECHNIQUE5
QUALITATIVE
Presence or absence of substance 
SEMI-QUANTITATIVE
Amount relative to control (e.g. IHC)
Brain/blood ratio (ml/g)
Ratio of concentration in brain tissue to that in blood
Clearance (ml/min)
Volume of plasma cleared of substance, through BBB, per 
unit time
Extraction fraction (unitless)
Fraction of substance leaving the blood during a single 
passage through vasculature
Brain uptake index (unitless)
Ratio of test to reference substance in brain, divided by 
ration in injectate, after a single pass
Permeability per weight of brain tissue, unadjusted for 
assuming uni- or bi-directional transport, and a different 
number of compartments
Permeability-surface product (ml/g/min)
Permeability (cm/min)
Permeability-surface product adjusted for regional 
capillary surface area
     INDICES OF BBB PERMEABILITY6
QUANTITATIVE
Fig. 1. Concepts in experimental design for in vivo study of BBB disruption in animals. A number of methods can be used, creating potential variability between studies. AAS,
atomic absorption spectroscopy; CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; EM, electron microscopy; IHC, immunohistochemistry; ISF, interstitial
fluid.
Table 2
Distinction between disruptive and non-disruptive BBB changes.
Disruptive BBB change Non-disruptive BBB change
Usually occurs at a histological level Usually occurs at a molecular level
Visible change in histological
architecture
No visible change in histological
architecture
Change in anatomy Change in function
Detected using inert tracers Not detected using inert tracers
Generally not substance-specific Substance-specific
Not a prerequisite for cellular traffic;
may occur if cellular traffic is
intense
Main mechanism underlying
change in cellular traffic
Nature of possible changes: tight
junction changes, denudation of
glycocalyx, endothelial cell
damage, increased vesicular
traffic, re-induction of fenestrae,
breakdown of glia limitans,
astrocytopathy in combination
with endothelial changes
Nature of possible changes:
cytokine production by
endothelial cells, upregulation
of endothelial cell receptors and
transporters, modulation of
astrocyte function, enhanced
pathogen neuroinvasion
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clear that the effects of LPS on the BBB are not universal. Since
some of the variability could be attributable to differences in
experimental technique, a multivariate logistic regression was per-
formed, with disruptive BBB change as the binary dependent vari-
able, and a number of predictor variables capturing differences in
experimental techniques:
 LPS dose, expressed as an absolute value or as a percentage of
species-specific lethal dose to correct for inter-species variation
(taken to be 2000 lg/kg in rodents (Dinges and Schlievert,
2001), 500 lg/kg in rabbits (Lee et al., 1991), and 1 lg/kg in foe-
tal sheep (Yan et al., 2004)). Since absolute LPS dose and % lethal
dose were correlated, the regression was performed twice with
either one or the other.
 Dosing protocol, classified as single or multiple, since the total
LPS dose was calculated cumulatively for multiple challenges.
 Species of experimental animal.
 Solute, classified as either an ‘indicator’ (unaltered solute) or a
‘tracer’ (solute altered for detection).
Fig. 2. Schematic illustration of disruptive and non-disruptive BBB changes during systemic inflammation. Relative proportions are not intended to be realistic. CAMs, cellular
adhesion molecules; GL, glia limitans.
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animal, potentially confounding estimates of permeability. The
remaining solutes were classified as ‘non-synthesised’. By these
criteria, immunoglobulin was classified as ’synthesized’,
labelled albumin as ‘non-synthesised’, and in studies detecting
the animal’s own unaltered albumin, we classified albumin as
‘synthesised’, as there is evidence that albumin may be pro-
duced with the brain and this process is enhanced by LPS expo-
sure (Ahn et al., 2008).
 Age of experimental animal, as either adult or infant (the latter
including all cases described as infant, neonatal, or foetal). An
age-related effect has been demonstrated (Stolp et al., 2005).
 Health of experimental animal, as either healthy or diseased. An
effect has been demonstrated in a number of disease models
compared to healthy controls, for example Alzheimer’s disease
(Takeda et al., 2013).
 Time course of permeability estimation, as either single (solute
assayed at single time point) or multiple (solute assayed at mul-
tiple time points). A time-dependent effect has been demon-
strated (Banks et al., 2015).
 Gender of experimental animal, as either male or female. An
effect of gender has been demonstrated (Maggioli et al., 2016).
17% of studies were missing data for this variable, leading to
its exclusion from the final analysis.Species was the only significant predictor explaining 16% of the
variance (p = 0.023) and correctly classifying 69% of cases. BBB
change was 4.1 times more likely in mice versus rats (p = 0.008).
LPS dose was not a significant predictor (absolute dose or percent-
age of lethal dose). However, a dose-dependent effect of LPS on the
BBB was observed when considering single studies using several
LPS doses (Allen, 1965; Banks et al., 2015; Jaeger et al., 2009;
Oshima et al., 2009). This indicates the confounding potential of
technical differences between studies, which when minimized
allow the detection of a dose-dependent effect of LPS dose on
BBB change. Finally, it is important to bear in mind that most
studies used septic doses of LPS, which limits the generalizability
of findings to more common less severe infections in human
patients.5.2. Mechanisms of disruptive BBB change in LPS models
A number of mechanisms have been described to account for
the BBB disruptive effects of LPS. Central to these mechanisms
are prostanoids and nitric oxide (NO) (Banks et al., 2015; Iwase
et al., 2000), both of which are synthesized by the LPS-stimulated
cerebrovascular endothelium and surrounding cells (Cao et al.,
1995; Minami et al., 1998).
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Evidence using TEER as a reflection of tight junction integrity
suggests that tight junction modification may be secondary to
prostanoids (de Vries et al., 1996a) and NO (Wong et al., 2004).
Other diffusible mediators include matrix metalloproteinases
(MMPs) (Qin et al., 2015) and reactive oxygen species (Yu et al.,
2015). Intracellular pathways include mitogen-activated protein
(MAP) kinase signalling (Qin et al., 2015), myosin light chain phos-
phorylation and F-actin rearrangement (He et al., 2011), and mito-
chondrial dysfunction (Doll et al., 2015). At protein translational
level, miR-155 contributes to changes in gene expression (Lopez-
Ramirez et al., 2014), which include decreased expression of occlu-
din and claudin-5 (Zhou et al., 2014). NFjB plays a role at gene
transcription level (Han et al., 2016).
5.2.2. Endothelial damage
Endothelial damage during systemic inflammation may con-
tribute to barrier dysfunction. Features include endothelial apopto-
sis, membrane abnormalities, and mitochondrial damage (Cardoso
et al., 2012). The induction of apoptosis may be mediated by MAP
kinase signalling (Karahashi et al., 2009).
5.2.3. Degradation of glycocalyx
Of emerging importance is the glycocalyx, a complex structure
of proteoglycans and sialoproteins lining the apical endothelium.
Although poorly studied in the CNS, accumulating evidence sug-
gests that a continuous glycocalyx is an important contributor to
barrier function, and that dysfunction leads to increased paracellu-
lar permeability (Woodcock and Woodcock, 2012). LPS models of
systemic inflammation demonstrate glycocalyx degradation
(Wiesinger et al., 2013). Degradation can be mediated by compo-
nents of the systemic inflammatory response, including tumour
necrosis factor-a (TNF-a) (Wiesinger et al., 2013), heparanase
(Chappell et al., 2008), ROS (Moseley et al., 1997), MMPs
(Lipowsky, 2012), and thrombin (Wiesinger et al., 2013).
5.2.4. Breakdown of glia limitans
The glia limitans is the innermost layer of the BBB. MMPs may
contribute to degradation of extracellular matrix components and
breakdown of the glia limitans (Cardoso et al., 2010).
5.2.5. Astrocyte changes
Astrocytes induce and maintain the BBB, and in particular form
the glia limitans (Sofroniew, 2015). Indeed, astrocyte destruction is
associated with BBB disruption (Asgari et al., 2015). Systemic LPS
may induce a number of structural and functional changes in astro-
cytes which could be relevant to disruptive BBB change. Some
in vivo studies show astrocyte proliferation and activation, fol-
lowed by astrocyte loss (Biesmans et al., 2013; Cardoso et al.,
2015), and another study demonstrates structural changes in
astrocytic end-feet (Fan et al., 2014), which could lead to disruptive
change. However, another study showed no morphological change
(Jeong et al., 2010). Systemic LPS also induces broad changes in
astrocyte gene transcription, including pro-inflammatory and cyto-
toxic pathways (Zamanian et al., 2012), and astrocytes are capable
of producing a range of substances associated with disruptive BBB
change, including interleukin-1b (IL-1b), interleukin-6 (IL-6), TNF-
a, and prostaglandins (Sofroniew, 2015). In vitro results are mixed;
LPS-induced disruptive BBB change was indifferent to the presence
of astrocytes in one study (Banks et al., 2015), but not another
(Gaillard et al., 2003).
5.3. Disruptive BBB change in other models of systemic inflammation
Other models of systemic inflammation have been used to
study their effects on BBB function, including polyinosinic:poly-cytidylic acid (poly I:C, a mimic of viral double-stranded RNA), live
non-neurotropic pathogens, sterile inflammatory stimuli, and
inflammatory mediators and cytokines. Table 3 summarises this
information, showing further evidence for BBB disruption during
systemic inflammation, and recapitulating mechanisms from LPS
models.6. Non-disruptive BBB change in systemic inflammation
If disruptive BBB change is absent during systemic inflamma-
tion, this does not mean that the BBB is unaltered, since non-
disruptive changes may occur. Morphological studies demonstrate
that tight junctions may remain intact during systemic inflamma-
tion (Papadopoulos et al., 1999), and changes in function may arise
through other routes, as described below. Importantly, the CNS
effects of systemic inflammation are not predicated on disruptive
BBB change (Banks et al., 2015).
6.1. Transporters
Models demonstrate a number of BBB transport pathways
which can be modified by systemic inflammation, including
down-regulation of the multi-functional efflux transporter P-
glycoprotein (Hartz et al., 2006), located on astrocytic foot pro-
cesses (Pardridge et al., 1997). Other transporters down-
regulated by systemic inflammation include those for organic
anions (Wittmann et al., 2015a), monocarboxylates (Wittmann
et al., 2015a), amino acids (Wittmann et al., 2015b), b-amyloid
(Jaeger et al., 2009), leptin (Nonaka et al., 2004), and prostaglandin
E2 (Akanuma et al., 2011). There is also evidence for inflammation-
induced up-regulation of influx carriers responsible for TNF-a
(Osburg et al., 2002), insulin (Xaio et al., 2001), monoamines (Wu
et al., 2015), lysosomal enzymes (Urayama et al., 2015), b-
amyloid (Jaeger et al., 2009), leukemia inhibitory factor (Pan
et al., 2008), and the viral protein gp120 (Banks et al., 1999).
6.2. Cytokines
Cytokines directly mediate some non-disruptive BBB changes.
Receptors for IL-1b, IL-6, and TNF-a are expressed on cerebral
endothelium (Ericsson et al., 1995; Vallières and Rivest, 1997;
Nadeau and Rivest, 1999), and systemic IL-1b and TNF-a cause
cerebral endothelial activation (Skelly et al., 2013). IL-1b causes
activation of endothelium preceding that of neighbouring brain
areas (Herkenham et al., 1998), suggesting that BBB activation is
an intermediate step. This is in keeping with LPS models mapping
expression of the nuclear transcription factor IjBa (Quan et al.,
2003). Interestingly, interferon-b (IFN-b) reduces transmigration
of Th1 lymphocytes, without any effect on diffusibility of albumin
(Prat et al., 2005), suggesting that the effect is not due to a change
in tight junctions but instead due to cytokine-induced non-
disruptive changes that discourage neuroinflammation.
6.3. Prostaglandins
LPS, TNF-a, and IL-1b promote cyclo-oxygenase (COX) expres-
sion in cerebral endothelium (Cao et al., 1995; Skelly et al.,
2013). The transcriptional profile of cerebral endothelial cells is
altered by systemic inflammation, to favour the production of
prostaglandin E2 (PGE2) (Vasilache et al., 2015). The response is
polarised, and PGE2 secretion is four times higher from the basal
compared to the luminal side (Moore et al., 1988). This provides
a mechanistic role for non-disruptive BBB changes in communicat-
ing inflammatory signals across the intact BBB, particularly in the
generation of fever. Systemic LPS also acts on BBB transport
Table 3
Disruptive BBB change in models of systemic inflammation, other than LPS.
Model Evidence for BBB disruption Evidence for possible mechanisms
Viral RNA Effect demonstrated with poly I:C (Daniels et al., 2014;
Wang et al., 2004).
 Dependent on TLR3 (Wang et al., 2004)
 Dependent on TNFR (Wang et al., 2004); likely involves systemic
production of TNF-a
 Local production of ROS and endothelial apoptosis shown in sys-
temic endothelium (Zimmer et al., 2011)
 Reduction in ZO-1 and claudin-5 co-localisation may impair tight
junctions (Daniels et al., 2014)
 Activation of calcium signalling and release of TNF-a and IL-6 from
brain tissue (Ott et al., 2012)
Systemic infection Effect demonstrated with:
 Staphylococcus aureus (Gregorius et al., 1976)
 Clostridium perfringens (Gregorius et al., 1976)
 Escherichia coli (du Moulin et al., 1985; Tsao et al., 2001)
 Streptococcus pneumoniae (Tsao et al., 2001)
 Caecal ligation and puncture (polymicrobial infection)
(Hofer et al., 2008; Yang et al., 2015)
 Dependent on TNF-a (Tsao et al., 2001)
Non-infective systemic
inflammation
Effect demonstrated with:
 Colitis (Natah et al., 2005; Hathaway et al., 1999)
 Pancreatitis (Farkas et al., 1998)
 Peripheral inflammatory pain induced by irritant injec-
tion into paw (Huber et al., 2002)
 Reduced expression of endothelial barrier antigen (a key BBB mar-
ker in rats) during colitis (Natah et al., 2005)
 Raised levels of TNF-a and IL-6 during pancreatitis (Hathaway et al.,
1999)
 Altered tight junction expression during peripheral inflammatory
pain (Huber et al., 2002)
Inflammatory mediators Effect demonstrated with (reviewed in Abbott, 2000):
 Bradykinin
 Serotonin
 Histamine
 Arachidonic acid
 Nitric oxide
Cytokines Effect demonstrated with:
TNF-a (Tsao et al., 2001)
 IL-1b (de Vries et al., 1996b)
 IL-6 (de Vries et al., 1996b)
 IFN-c (Daniels et al., 2014)
 TNF-a: some evidence for reduced tight junction expression
(Förster et al., 2008; Daniels et al., 2014)
 IL-1b: effect dependent on COX (de Vries et al., 1996b)
 IFN-c: down-regulation of tight junction proteins (Minagar et al.,
2003)
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increased brain concentrations (Akanuma et al., 2011). Conversely,
changes in prostaglandin levels may also modify transport func-
tions, for example insulin influx (Xaio et al., 2001).
6.4. Cellular transmigration
Passage of cells across the BBB occurs primarily at the post-
capillary venules (Bechmann et al., 2007) and may occur through
a paracellular or transcellular route. Micrographs clearly demon-
strate the encapsulation of a small amount of plasma that accom-
panies the cell through its course across the endothelium (Wolburg
et al., 2005), and earlier descriptions of transendothelial channels
observed in various CNS pathologies (Lossinsky and Shivers,
2004) may be the aftermath of diapedesis. Hence although cellular
influx into the CNS is physiologically non-disruptive, it may result
in disruptive BBB change if pronounced.
Leucocyte recruitment across the BBB in response to systemic
inflammation can be demonstrated for lymphocytes (Banks et al.,
2012), neutrophils (Bohatschek et al., 2001) and monocytes
(Wang et al., 2008). Mechanistically, systemic inflammation can
promote leukocyte transmigration at various points during the
two-step passage through (1) endothelium and (2) glia limitans.
6.4.1. Passage through endothelium
(a) Rolling is mediated mainly by endothelial P- and E-selectins
binding to leukocyte P-selectin glycoprotein 1 (PSGL1). BBB
endothelial cells do not constitutively express P-selectin,
which may play a role in immune privilege, but P-selectin
expression can be induced by exposure to TNF-a or IL-1b
in vitro (Barkalow et al., 1996). In vivo systemic TNF-a pro-motes expression of brain microvessel P- and E-selectin,
which are both required for cellular recruitment (Carvalho-
Tavares et al., 2000). Systemic LPS has a similar effect on
P-selectin (Zhou et al., 2009). Degradation of the glycocalyx
in systemic inflammation enhances and may be required for
leukocyte interactions, possibly due to exposure of endothe-
lial markers which are normally obscured (Lipowsky, 2012).
(b) Activation of the leucocyte for subsequent arrest is induced
by chemokines, which lead to conformational changes in
leukocyte integrins such as LFA-1 (lymphocyte function-
associated antigen 1) and VLA-4 (very late antigen-4) which
enhance their binding to endothelial ligands. BBB endothe-
lial production of CCL2 (CC-motif ligand 2) is stimulated by
pro-inflammatory cytokines or LPS (Chui and Dorovini-Zis,
2010). The predominant source of CXCL2 (CXC-motif ligand
2) appears to be microglia (Zhou et al., 2009), which are also
stimulated by LPS via TLR4 (Zhou et al., 2006). Activated
astrocytes may also be a source of chemokines (Sofroniew,
2015), although some evidence suggests that reactive
astrocytes may suppress cellular infiltration (Bush et al.,
1999).
(c) Arrest of the leucocyte occurs when endothelial cell adhesion
molecules (CAMs) bind to leucocyte integrins, and is fol-
lowed by diapedesis. The expression of CAMs such as
ICAM-1 (intercellular adhesion molecule 1) on the BBB is
usually low, but is promoted by inflammation (Bohatschek
et al., 2001). The effect of systemic inflammation on neu-
trophil recruitment across the BBB is dependent on ICAM-1
(Bohatschek et al., 2001). Cytokine mixtures from the serum
of septic patients cause leucocyte adhesion to BMECs in vitro,
which is dependent on integrins and ICAM-1 (Blom et al.,
2015).
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After transendothelial passage, leukocytes enter the perivascu-
lar space. The second step of neuroinflammation requires passage
across the glia limitans to enter the brain parenchyma proper
(Bechmann et al., 2007), and is dependent on degradation of base-
ment membrane components by MMP-2 and MMP-9 (Agrawal
et al., 2006). LPS up-regulates endothelial MMP-2 expression (Qin
et al., 2015). Macrophages also play a crucial role in the second
step (Tran et al., 1998), and perivascular macrophages are activated
by systemic LPS (Mato et al., 1998). Pericytes, located in the
perivascular space, are also stimulated by LPS and are able to
attract neutrophils and produce MMPs (Pieper et al., 2013).
6.5. Pathogen neuroinvasion
A wide variety of mechanisms underlie invasion of the CNS with
pathogens. It has been shown that LPS may enhance entry of virus
(Lustig et al., 1992) or virus-infected cells (Wang et al., 2008) into
the CNS, associated with disruptive change. However, non-
disruptive BBB changes during systemic inflammation may also
promote neuroinvasion of pathogens. For example, systemic LPS
enhances the transcellular transport of the human immunodefi-
ciency virus (HIV), independent of changes in TEER, via a mecha-
nism involving luminal stimulation by IL-6 and granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Dohgu et al.,
2011), and intracellular MAP kinase signalling (Dohgu and Banks,
2008). This effect of LPS also involves pericytes, in response to
polarised secretion from endothelial cells (Dohgu and Banks, 2013).
7. Clinical relevance
7.1. BBB is altered in CNS pathology
Alzheimer’s disease (AD), multiple sclerosis (MS), and CNS dys-
function in systemic infection are examples of conditions which
are primarily neurodegenerative, neuroinflammatory, or systemic.
In many cases it is not clear whether BBB changes are the cause or
effect of neuropathology, and it is possible that BBB changes and
neuropathology drive each other in a self-perpetuating manner,
contributing to disease progression.
7.1.1. Alzheimer’s disease
As reviewed in detail elsewhere (Erickson and Banks, 2013),
BBB changes in AD may be an early and important step in patho-
genesis. Accumulation of b-amyloid may damage the neurovascu-
lar unit and lead to disruption. Other changes result in the
decreased clearance of b-amyloid, via changes in transport proteins
such as P-glycoprotein, LRP-1 (low-density lipoprotein receptor-
related protein 1), and RAGE (receptor for advanced glycation
end products).
7.1.2. Multiple sclerosis
A key step in the pathogenesis of MS is thought to be the infil-
tration of auto-reactive CD4+ T-lymphocytes into the CNS, after
activation in the periphery. BBB disruption has been demonstrated
in experimental autoimmune encephalomyelitis (EAE), and the
clinical severity can be linked to the degree of BBB disruption
(Fabis et al., 2007). EAE involves loss of tight junction proteins
(Wolburg et al., 2003). Up-regulation of miR-155 in active MS
lesions (Junker et al., 2009), with corresponding down-regulation
of BBB tight junction components (Lopez-Ramirez et al., 2014),
may be involved. Imaging studies show BBB disruption in
normal-appearing white matter in MS (Cramer et al., 2014), and
BBB breakdown precedes the development of new lesions
(Alvarez et al., 2015). Non-disruptive BBB changes which favourneuro-inflammation are also an important feature of MS, and
include increased expression of adhesion markers such as P-
selectin (Kerfoot and Kubes, 2002) and ICAM-1 (Bö et al., 1996)
as well as chemokines such as CXCL12 (CXC-motif ligand 12)
(Krumbholz et al., 2006).
7.1.3. CNS dysfunction during systemic infection
CNS dysfunction associated with systemic infection is common,
and syndromes include sickness behaviour and delirium. In the
context of sepsis this syndrome is known as septic encephalopathy.
A key step in pathogenesis is the systemic production of pro-
inflammatory cytokines such as TNF-a and IL-1b, which then act
on the brain. BBB cytokine transport systems are likely to play a
role in permitting the passage of these signals (Banks, 2005).
The degree of systemic inflammation may be relevant. During
mild systemic infections, non-disruptive BBB changes are likely
to be more relevant while both non-disruptive and disruptive
changes may occur during sepsis. As discussed above, the BBB acts
as a signalling intermediate, secreting prostaglandins such as PGE2
into the brain, in response to systemic stimuli, leading to fever,
anorexia, and malaise. Blood-to-brain transport of TNF-a is
increased during systemic inflammation, by up-regulation of
receptor-mediated transcytosis (Osburg et al., 2002). Brain uptake
of insulin is also increased (Xaio et al., 2001), where it could pro-
mote anorexia and weight loss. During sepsis, there is some evi-
dence for disruptive BBB change, based on increased CSF protein
(Young et al., 1992) and MRI changes (Sharshar et al., 2007).
7.2. Neuropathology sensitises the BBB to systemic inflammation
The BBB in pathology may not have the same response to sys-
temic inflammation as the healthy brain. Subtle BBB changes in
the initial stages of disease could make the BBB more vulnerable
to systemic inflammation than is normal, and in particular may
predispose to disruption.
7.2.1. Alzheimer’s disease
For example, BBB disruption during systemic inflammation is
greater in AD mice than in wild-type controls (Takeda et al.,
2013). This correlates with the magnified brain inflammatory
responses seen in AD models in response to systemic inflamma-
tion, despite normal systemic inflammatory responses (Takeda
et al., 2013). Microglial priming could sensitise the BBB to disrup-
tive change and cellular infiltration during systemic inflammation,
as demonstrated in a mouse model of ageing (Raj et al., 2015).
7.2.2. Multiple sclerosis
BBB changes in MS models include increased pinocytotic activ-
ity across the BBB (Claudio et al., 1989), and increased activity of
the TNF-a transporter system (Pan et al., 1996); both of which
would potentiate the central effects of circulating cytokines during
systemic inflammation. Astrocytopathy in conditions such as MS
and neuromyelitis optica could also contribute to BBB sensitization
since lack of astrocytes sensitises the BBB to disruptive changes
induced by systemic inflammation (Asgari et al., 2015; Gaillard
et al., 2003). Microglia are the major source of CXCL2 (Zhou
et al., 2009), and endothelial-bound chemokines at the BBB could
alter the conformation of LFA-1 on leucocytes to induce their arrest
and subsequent transmigration.
7.2.3. Stroke
The BBB is disrupted in ischaemic stroke (Sandoval and Witt,
2008), and is sensitised to further disruptive changes by systemic
inflammation (Denes et al., 2011). Correspondingly, brain damage
and mortality is exacerbated by systemic inflammation in experi-
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comes (Palasik et al., 2005).
7.3. BBB changes induced by systemic inflammation may contribute to
disease progression
Systemic inflammation, typically in the form of urinary or chest
infection, is a common cause for deteriorating symptoms in neuro-
logical diseases like AD and MS. An established mechanism is the
increased sensitivity to systemic inflammation of primed CNS-
resident immune cells in these conditions (Perry and Holmes,
2014); this is facilitated by the BBB changes discussed in this
review. In addition, there is some evidence that BBB changes dur-
ing systemic inflammation may contribute to disease progression
by affecting the primary pathological process, separate from the
increased sensitivity of the ongoing CNS inflammatory process to
systemic inflammation.
7.3.1. Alzheimer’s disease
Both acute and chronic systemic inflammation accelerate the
progression of AD (Holmes et al., 2009). Systemic inflammation
in AD is associated with several non-disruptive BBB changes which
further favour b-amyloid partitioning into the brain, by increasing
influx and decreasing efflux (Jaeger et al., 2009). Correspondingly,
systemic inflammation accelerates hippocampal amyloid deposi-
tion (Weintraub et al., 2014). Reduced expression and abnormal
localisation of LRP-1, which exports b-amyloid has been reported
in vitro (Erickson et al., 2012). Systemic inflammation also results
in reduced bulk flow of CSF/ISF across the BBB, which could further
impair b-amyloid clearance (Erickson et al., 2012). In summary,
BBB alterations induced by systemic inflammation in AD may
increase amyloid deposition and contribute to disease progression.
7.3.2. Multiple sclerosis
Systemic inflammation exacerbates CNS disease in relapsing-
remitting MS (RRMS), and these exacerbations have been shown
tooccur in the absence or presence of disruptiveBBBchanges inboth
EAE (Moreno et al., 2011; Serres et al., 2009) andMS (Buljevac et al.,
2002; Correale et al., 2006). In EAE, lesional heterogeneity in the
occurrence of disruptive BBB change during systemic inflammation
has been demonstrated (Serres et al., 2009). Disruptive BBB change
in other pathologies has been found to be associated with increased
serum levels of myelin basic protein (Hill et al., 2000), a major
immunological target inMS. Thus BBB changes induced by systemic
inflammation have potential to alter MS disease.8. Conclusion
In this article we have reviewed the current evidence on the
effects of systemic inflammation on BBB function in animals and
humans, in the healthy and diseased brain. Unanswered biological
questions remain regarding the nature and mechanisms of BBB
changes in systemic inflammation in humans, including:
 How do BBB responses to systemic inflammation differ between
health and disease in the human brain?
 How significant is the role of the BBB in mediating the effects of
systemic inflammation on neurological disease progression?
 What is the regional variability of BBB changes in systemic
inflammation, and how does this correlate with clinical features
of inflammation-associated CNS dysfunction?
 What role does the glycocalyx play in mediating BBB changes?
 What therapeutic strategies can be safely used to mitigate the
undesirable effects of systemic inflammation on the BBB in
humans?The development of techniques to quantify disruptive BBB
changes will aid human study, including advanced imaging proto-
cols such as dynamic contrast-enhanced MRI, as well as serum
biomarkers. The exploration of brain-specific glycocalyx markers
would be invaluable. Additional techniques are also required to
investigate non-disruptive BBB changes in vivo, for example PET
imaging of transport proteins and cellular adhesion markers. Such
techniques will help determine to what degree BBB changes con-
tribute to disease expression. Finally, the clinical implications of
these findings raise the possibility of designing treatments to mod-
ify neurological disease by targeting systemic inflammation and
the BBB.
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